It is almost 20 years since the first steroid receptor cDNAs were cloned, a development that led to the concept of a superfamily of ligand-activated transcription factors: the nuclear receptors. Natural ligands for nuclear receptors are generally lipophilic in nature and include steroid hormones, bile acids, fatty acids, thyroid hormones, certain vitamins and prostaglandins. Nuclear receptors act principally to directly control patterns of gene expression and play vital roles during development and in the regulation of metabolic and reproductive functions in the adult organism. Since the original cloning experiments, considerable progress has been made in our understanding of the structure, mechanisms of action and biology of this important family of proteins.
Introduction
The physiological actions of steroid hormones have been recognized for more than 100 years. The role of the testes in producing a 'male hormone' was demonstrated experimentally by the pioneering experiments of A.A.
Berthold in 1849 [1] , while in 1896, G. Beatson showed that removal of the ovaries led to regression of breast tumours [2] . It was then only a matter of time before the molecular structures of these versatile messengers were determined and they were chemically synthesized. The first breakthrough in unravelling the molecular mechanism of action of steroid hormones was undoubtedly the availability of radiolabelled steroid molecules that allowed the identification of receptor proteins within target cells and led to the formulation of the two-step model for steroid action by Jensen and colleagues (reviewed in [2] ). Some 20 years later, in the mid-1980s, the next dramatic development took place with the cloning of the cDNAs for the glucocorticoid receptor (GR), the oestrogen receptor (ER) and the progesterone receptor (PR). This rapidly led to the cloning of receptor proteins for non-steroid ligands, such as thyroid hormones (TRs) and retinoic acid (RAR), and the nuclear receptor superfamily was born ( [3] and references therein).
"Evolution… is a change from an indefinite, incoherent homogeneity, to a defined coherent heterogeneity" Herbert Spenser (First Principles)
The nuclear receptor superfamily represents a disparate collection of proteins that share a common structural organization. These proteins in many, if not all, cases transduce signals that are important for animal development, metabolic regulation and reproduction. Representatives of the family have been identified in all classes of metazoans, but, strikingly, appear to be absent in yeasts and plants (see Chapter 2) . A comparison of amino-acid sequences of the DNA-and ligand-binding domains has led to the classification of six subfamilies, and compelling evidence that the diversity within the family arose from two separate gene duplication and diversification events. It also seems likely that the ancestral protein was an orphan receptor and that ligand binding was an acquired property that occurred more than once independently (see Chapter 2) . The availability of complete genome sequences for a number of metazoans has revealed some interesting observations regarding the occurrence of nuclear receptors in different species. The human genome sequence reveals 48 members of the family, with just under half (21 genes) representing receptors with known ligands. Drosophila contains 21 family members, while the nematode worm Caenorhabditis elegans has more than 200 nuclear receptor genes, but lacks any of the known ligand-binding members of the family.
"What is the character of a family to a hypothesis?" Laurence Sterne (Tristram Shandy)
Members of the nuclear receptor superfamily have a modular structure that consists of a C-terminal ligand-binding domain (LBD) linked by a hinge region to the DNA-binding domain (DBD), which is then flanked by a unique Nterminal domain (NTD) (Figure 1 ). The NTD is the most variable region in terms of amino-acid sequence and length, ranging from several hundred amino acid residues for certain steroid receptors to less than 100 for TR␣, RAR and the vitamin D receptor (VDR). This region contains sequences [termed activation function 1 (AF1)] that are important for receptor-dependent transactivation. Structural analysis of the AF1 domain of several members of the family indicates that this region is structurally flexible and adopts a more folded conformation upon specific protein-protein interactions (see Chapter 3) .
The folding of the core DBD is a defining feature of this family of transcription factors. The DBD is characterized by eight conserved cysteine residues that co-ordinate two zinc ions and consists of two ␣-helices that are folded perpendicular to each other (see Chapters 3 and 5). The first zinc module forms the 'recognition helix', which mediates specific amino-acid-base-pair interactions. In addition, a region flanking the core DBD, termed the 'C-terminal extension' (CTE) also plays a role in protein-DNA and/or protein-protein interactions. The CTE has been shown to form an ␣-helix for a number of non-steroid receptors [i.e. retinoid X receptor (RXR), TR and VDR], but appears to be disordered in steroid-binding members of the family (see Chapter 5) . Members of the nuclear receptor superfamily recognize and bind DNA half-sites consisting of the sequences AGAACA or AGGTCA; the latter can be arranged as inverted repeats with 3-base-pair spacing, as direct repeats with variable spacing or as single elements. The different configurations of half-sites permit members of the family to bind as homodimers (i.e. The common structural organization of nuclear receptors that is observed at the protein level belies the variety in structure of both natural ligands, including steroids, oxysterols, bile acids, thyroid hormones, retinoids and prostaglandins, as well as a plethora of drugs, that can bind and regulate receptor activity ( Figure 3) . However, are all members of the family actually receptor proteins? Clearly, some of members of the family are bona fide receptor proteins with identified and well-characterized natural ligands; however a significant number of family members have yet to have a ligand identified and have been termed 'orphan receptors', and, in certain cases, it seems likely that no ligand is required for protein function. In addition to ligand binding, the LBD also contains sequences that mediate protein-protein interactions, including dimerization, interactions with molecular chaperone complexes (see Chapter 4) , and the binding of co-activators (see Chapters 3 and 6) or co-repressors (see Chapter 7). 
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The three-dimensional structures of the LBD of both ligand-activated and orphan receptors have been solved (see Chapter 3). The overall folding of this domain is remarkably conserved, but what is striking are the differences in the dimensions of the 'ligand-binding pocket' and the correlation with putative ligands. Thus, PPAR␥ has a relatively large binding pocket, consistent with the range of natural and xenobiotic ligands that can bind and activate this receptor. This contrasts with the binding pocket of other receptors with more restrictive ligand profiles. Of particular note is the structure of the LBD of the NGFI-B subfamily of orphan receptors, for which the putative ligand-binding pocket is occupied by the bulky ring side-chains of four phenylalanine residues, which appear to act as an 'internal ligand' (see Chapter 3) .
Apart from the obvious regulatory action of natural ligands and drugs, how else might the functions of these proteins be controlled? It is now clear that the binding of nuclear receptors to specific DNA sequences within the genome may not simply function to tether the protein to promoter and/or enhancer regions. There is good evidence that DNA response elements can serve as allosteric regulators of receptor function (see Chapters 3 and 5). Another means of potential regulation that has generated considerable excitement is different forms of post-translational modification of receptor proteins, including phosphorylation, acetylation, sumoylation [modification with SUMO-1 (small ubiquitin-like modifier 1)] or ubiquitination (Figure 1) . In many cases, the site, or sites, of modification has been identified, with serine and lysine residues within the NTD being phosphorylated and sumolyated respectively, and lysine residues within the hinge region of the AR and ER being acetylated (see Chapters 3, 5 and 6). Clues from recent studies suggest that certain phosphorylation and acetylation events of nuclear receptors can modulate protein-protein interactions of the receptor with the transcriptional machinery [4] [5] [6] [7] . Similarly, sumolyation of the AR and GR may modulate receptor-protein interactions or receptor stability [8] . Studies with phosphorylation site-specific antibodies have revealed a role for site-specific phosphorylation and the intracellular location of the GR [9] . The continuing challenge is to determine the functional and/or structural significance of individual modifications and to determine if such modifications may actually act co-operatively.
"Action is transitory, -a step, a blow…" William Wordsworth (The Borders)
An important question when considering the mechanism of action of nuclear receptors is, are these proteins always nuclear? In the absence of a hormone, there is good evidence to suggest that a significant proportion of the receptors for androgens, glucocorticoids and progesterone are found in the cytoplasm, bound to a molecular chaperone complex (see Chapter 4). Molecular chaperones play important roles in steroid receptor signalling by maintaining the receptor in a conformation that can bind a hormone, in trafficking of the receptor complex from the cytoplasm to the nucleus and in the possible recycling of the receptor protein to switch off the response (see Chapters 4 and 6). In addition to the intracellular location of the inactive steroid receptors, recent studies have demonstrated that rapid responses to progesterone and oestradiol involve the extranuclear action of the classical receptor proteins (i.e. PR and ER) (see Chapter 8) . The evidence highlights the action of these receptors at the plasma membrane, resulting in the activation of the tyrosine kinase c-src and the subsequent downstream mitogen-activated protein kinase signalling pathway. The principal function of this family of proteins remains the direct regulation of gene transcription, which thus necessitates the nuclear location of the protein. Transcriptional regulation is a complex process that is mediated at a number of levels in eukaryotic cells. Not only is the transcription process itself subject to direct regulation, but the structure of the genetic material is modulated so as to permit or impede transcription via the packaging of chromosomal DNA with histone proteins as nucleosomes (see Chapter 6) . Increasingly, attention is now being focused on investigating how these ligand-activated transcription factors regulate gene expression. A major breakthrough has been the identification of a diverse range of proteins that interact with nuclear receptors in either the presence (see Chapter 6) or absence (see Chapter 7) of specific ligands. Of particular interest has been the realization that some of these proteins, either alone or as part of multi-subunit complexes, harbour enzymic activities. The most notable enzymes associated with nuclear receptors include histone acetyltransferases/deacetylases, methyltransferases, ATPdependent helicases and kinases (see Chapter 6 ).
It appears that, broadly speaking, nuclear receptors activate gene expression in a two-step process involving (i) opening of the chromatin structure, through histone modification and/or ATP-dependent remodelling of nucleosomes, and (ii) direct recruitment of the transcriptional machinery through interactions with key components including 'mediator' subunits, Med150 and Med220, and the basal transcription factors TBP (TATA-box-binding protein), transcription factor IIB (TFIIB), TFIIF and TFIIH (see Chapter 6) . In contrast, the negative regulation of gene expression by nuclear receptors appears to involve (i) altered receptor-DNA interactions on so-called 'negative response elements', (ii) interactions with co-repressor complexes that lead to a closed chromatin structure, and (iii) protein-protein interactions that disrupt assembly of the transcriptional machinery or the action of other transcription factors (see Chapter 7). Techniques such as fluorescence recovery after photobleaching (FRAP) [10] and chromatin immunoprecipitation (ChIP) [11] [12] [13] have revealed the dynamic nature of receptor-DNA interactions and the cyclic recruitment of different co-activator complexes to natural target genes. The unravelling of the molecular details of these processes is very much an area of intense research in many laboratories.
"Accidents will occur in the best-regulated families" Charles Dickens (David Copperfield)
Given the important role that nuclear receptors play in development and regulatory processes in the adult animal, it is not surprising that disruption of these signalling pathways can have severe consequences for health. Mutations in the AR (see Chapter 9), GR (see Chapter 10), TR (see Chapter 12) and vitamin D3 receptor (reviewed in [14] ) result in hormone resistance syndromes causing (i) in male differentiation and fertility, (ii) disruption of glucocorticoid homoeostasis, (iii) growth and developmental defects, and (iv) skeletal defects respectively. Resistance to androgens and vitamin D3 result from loss-of-function mutations clustering in the DBD and LBD, while general resistance to thyroid hormones results from mutations within the TR␤ gene and involve the dominant negative action of the mutant receptor protein; the mutations having been mapped to discrete regions within the LBD of the three receptors. The identification of ligands for orphan receptors and the previously unsuspected signalling pathways has also opened up the possibility of genetic alterations in nuclear receptors in the underling pathologies of metabolic disorders such as diabetes and obesity (see Chapter 12) .
Polymorphisms and mutations in the nuclear receptor genes have also been correlated with or been implicated in the risk of a wide range of conditions, including certain cancers, most notably breast (ER) and prostate cancer (AR), neurodegenerative disorders [ER, AR and NUR-related factor 1 (NURR1) /NGFI-B], cardiovascular disease (ER and TR) and a range of psychological conditions (ER and NURR1/NGFI-B) (see .
Considerable insight into the physiological roles of members of the nuclear receptor superfamily has also been gained from transgenic animal studies, including both 'knock-out' and 'knock-in' strategies (see . Such approaches have also be used successfully to investigate the role of co-activator and co-repressor proteins: for example, disruption of the gene for steroid receptor co-activator 1 (SRC-1) resulted in mice with symptoms of hormone-resistance syndromes (see Chapters 7 and 12) . A better understanding of the mechanism of action of members of the nuclear receptor superfamily and the role that genetic alterations play in different diseases will ultimately yield important insights into the disease process and the development of new or improved therapeutic strategies that will target specific receptors in a tissue specific manner.
Conclusions and future perspectives
The last 20 years have seen tremendous progress in our understanding of the structure-function relationships of members of the nuclear receptor superfamily. This has included the isolation of receptor cDNAs, the solving at atomic resolution of the structure of isolated DBDs and LBDs, the identification of binding partners and a clearer appreciation of the role that mutations in nuclear receptors play in a wide range of pathological states. The future should be just as challenging and exciting, and we may reasonably expect progress in a number of areas.
• The three-dimensional structure of a full-length member of the nuclear receptor superfamily, probably in a complex with a DNA response element and/or peptides derived from co-regulatory proteins.
• A better understanding of the role of different post-translational modifications of nuclear receptors and co-regulatory proteins, and the enzymes responsible, in nuclear receptor signalling.
• Identification of gene targets and regulatory networks for individual nuclear receptors.
• A clearer understanding of the integration of different signalling pathways in cells, tissues and the whole organism in both health and disease states.
As befits such a large family of proteins that is involved in development, metabolic regulation and reproduction, there is intensive research into all aspects of nuclear receptors. In the future, it is assured that there will be further dramatic developments as researchers strive to understand the biology and physiology of nuclear receptors, the structural and biochemical basis for receptor action, and the role that genetic alterations in receptor signalling play in disease. The chapters that follow explore these and related aspects of nuclear receptor signalling in more detail, giving a good summary of our current knowledge and future directions in this ever-growing area of research. 
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